NKTR : Analysis & Opinions

  1. Will Baxter International (BAX) Disappoint Earnings in Q4? - ...

    January 27, 2015
    Baxter International Inc. (BAX) is set to report fourth-quarter 2014 results on Jan 29.
  2. Nektar Therapeutics (NKTR): New Analyst Report from Zacks Equity ...

    January 15, 2015
    Nektar Therapeutics reported earnings of $0.53 per share in the third quarter of 2014, well above the Zacks Consensus Estimate ...
  3. Baxter Seeks FDA Approval of BAX111 to Advance VWD Cure - Analyst ...

    December 23, 2014
    Baxter International Inc. (BAX) filed a BLA with the FDA for the approval of BAX 111 - an investigational drug for the treatment ...
  4. New Ratings

    October 9, 2012
    New York, May 23rd (TradersHuddle.com) - These are the research analyst new ratings before the market open. Travelers (NYSE:TRV) ...
  5. The Salix Story Keeps Improving

    January 18, 2012
    Salix is a great candidate for growth investors.
  6. The Curious And Complicated Case Of MannKind

    December 15, 2010
    MannKind is a classic high-risk high-reward biotech story.
  7. There Is Life After Death, At Least In Biotech

    June 22, 2010
    Clinical failure is not the end of the story for all biotechs. How do some survive while others disappear?
Trading Center